LabCorp Extends Bid for Orchid Cellmark for Ninth Time | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America has extended its cash tender offer for Orchid Cellmark for the ninth time as it continues to address questions from regulators about the proposed $85.4 million deal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.